Applied Ventures Broadens Portfolio with Strategic Biotechnology Investment

Applied Ventures, LLC, the venture capital arm of Applied Materials, Inc. and a leading corporate venture firm, announced that it has participated in a Series B financing round for Twist Bioscience Corporation, an advanced biotechnology company developing a proprietary semiconductor-based technology platform for synthetic gene manufacturing.

Twist’s manufacturing process is intended to enable large-scale, high-throughput construction of genetic designs that aim to overcome industry inefficiencies by synthesizing DNA on silicon instead of traditional plastic. The funds provided by Applied Ventures will be used to collaborate on platform development and enable next-generation silicon-based technologies with improved throughput, quality and cost. The investment also presents an opportunity for Applied Materials to leverage its expertise in precision materials engineering to add value to cutting-edge and potentially disruptive applications in emerging biotechnology markets.

“Applied Ventures’ investment in Twist underscores our investment strategy to use our core strength in precision materials engineering to promote innovation wherever it happens across the world,” said Eileen Tanghal, general manager of Applied Ventures. “We are excited to expand our portfolio to include bioscience technology applications and look forward to helping commercialize Twist’s sophisticated technology to enhance personalized healthcare and agriculture production as we know it.”

Twist’s 10,000-well silicon-based manufacturing platform is capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. By transitioning the industry from existing plastic and glass substrates to silicon, the company’s technology has the potential to accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production and related new applications such as in vivo diagnostics, biodetection and data storage.

“We believe Twist’s proprietary semiconductor-based DNA synthesis process using a silicon platform will provide increased speed, quality and throughput, as well as reduced cost, to the design/build/test research cycle for developing better biologics, diagnostics, industrial chemicals and agbio products,” said Emily Leproust, Ph.D., CEO, Twist Bioscience Corporation. “Applied Ventures’ investment bolsters our financial position and provides us a strategic partner with exceptional expertise in precision materials engineering to assist our aggressive development efforts to commercialize our first products in 2015.”